

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL  
FORM

AUG 04 2005

(to be used for all correspondence after initial filing)

Mail Stop **Amendment**

Application Number	10/524,302
Filing Date	July 28, 2003
First Named Inventor	Stephan Schwers
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	1300-0014

## ENCLOSURES (Check all that apply)


- No fee due**  
 Fee Transmittal  
 Fee(s) due  
 Fee Transmittal  
 Check for \$
- Charge any underpayment or credit any overpayment to Deposit Account No. 18-0580**
- Return postcard**  
 Amendment/Reply  
 After Final  
 Affidavits/declaration(s)
- Extension of Time Request  
 Express Abandonment Request
- Information Disclosure Statement & Form(s) PTO-1449**  
 **Copies of cited references (AA-AF)**
- Certified Copy of Priority Document(s)  
 Response to Missing Parts / Incomplete Application  
 Response to Missing Parts under 37 CFR 1.52 or 1.53

- Drawing(s)  
 Licensing-related Papers  
 Petition  
 Request to Add Omitted Inventor in Provisional Application Under 37 CFR 1.48(d)  
 Power of Attorney, Revocation, Change of Correspondence Address  
 Terminal Disclaimer  
 Request for Refund  
 CD, Number of CD(s):

- After Allowance Communication to a Technology Center (TC)  
 Appeal Communication to Board of Appeals and Interferences  
 Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  
 Proprietary Information  
 Status Letter  
 Other Enclosure(s) (please identify below):


Remarks:

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name (print/type)	David A. Sadewasser, Reg. No. 55,587 Reed Intellectual Property Law Group	Telephone	(650) 251-7700
Signature		Date	August 2, 2005

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Name (print/type)	Joe Clark	Date	August 2, 2005
Signature		Date	August 2, 2005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of:  
Stephen SCHWERS et al.

Serial No.: 10/524,302 Group Art Unit: Unassigned

**Title: GENETIC POLYMORPHISMS SENSITIVELY PREDICTING ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY**

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97(b)(3)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request that the Examiner review and make of record the references identified in this paper. A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

<b>U.S. PATENT DOCUMENTS</b>		
Document No.	Issue Date / Publication Date	Patentee / Applicant

FOREIGN PATENT DOCUMENTS		
Document No.	Publication Date	Country
WO 99/64630	12/16/99	PCT

OTHER DOCUMENTS	
ASSMANN, et al., <i>Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men</i> , Am. J. Cardiol. 77:1179-1184 (1996).	
LAZAROU, <i>Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies</i> ," J. Am. Med. Assoc. 279:1200-1205 (1998).	
LUSIS, <i>Atherosclerosis</i> , Nature 407:233-241 (2000).	
ROSS, <i>The pathogenesis of atherosclerosis: a perspective for the 1990s</i> , Nature 362:801-809 (1993).	
UCAR, et al., <i>HMG-CoA reductase inhibitors and myotoxicity</i> , Drug Safety 22:441-457 (2000).	

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Office Action on the merits, pursuant to 37 C.F.R. § 1.97(b)(3), no fee is required for filing this Information Disclosure Statement; however, if the Office deems that a fee is necessary to process this paper, the Commissioner is authorized to charge such fee to Deposit Account No. 18-0580.

Respectfully submitted,

By:

  
\_\_\_\_\_  
David A. Sadewasser  
Registration No. 55,587

REED IP LAW GROUP  
1400 Page Mill Road  
Palo Alto, California 94304  
(650) 251-7700 Telephone  
(650) 251-7739 Facsimile

F/Document/9950/0002/10/Supp IDS

Substitute for form 1449A/PTO				<i>Complete if Known</i>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Application Number</b>	10/524,302		
Sheet	1	of	1	<b>Intl. Filing Date</b>	July 28, 2003		
				<b>First Named Inventor</b>	Stephen SCHWERS, et al.		
				<b>Art Unit</b>	Not Yet Assigned		
				<b>Examiner Name</b>	Not Yet Assigned		
				<b>Attorney Docket Number</b>	1300-0014		

<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate

<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
/MKZ/	AA	WO 99/64630	12/16/99	PCT			

<b>OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS</b>							
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T
/MKZ/	AB	ASSMANN, et al., <i>Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men</i> , Am. J. Cardiol. 77:1179-1184 (1996).					
/MKZ/	AC	<i>LAZAROU, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies</i> ," J. Am. Med. Assoc. 279:1200-1205 (1998).					
/MKZ/	AD	<i>LUSIS, Atherosclerosis</i> , Nature 407:233-241 (2000).					
/MKZ/	AE	<i>ROSS, The pathogenesis of atherosclerosis: a perspective for the 1990s</i> , Nature 362:801-809 (1993).					
/MKZ/	AF	<i>UCAR, et al. HMG-CoA reductase inhibitors and myotoxicity</i> , Drug Safety 22:441-457 (2000).					

Examiner Signature	/Mary K Zeman/	Date Considered	10/22/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.